The relationship between PON1 phenotype and PON1-192 genotype in detoxification of three oxons by human liver

Drug Metabolism and Disposition

Volumn 35, Issue 2, 2007, Pages 315-320

  Mutch, Elaine ^a   Daly, Ann K ^a   Williams, Faith M ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; CHLORPYRIFOS OXON; DIAZOXON; PARAOXON; PHENYLACETIC ACID; PHOSPHOROTHIOIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DETOXIFICATION; ENZYME ACTIVITY; ENZYME LOCALIZATION; FEMALE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROLYSIS; LIVER METABOLISM; LIVER MICROSOME; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TOXICOKINETICS;

ADULT; AGED; ARYLDIALKYLPHOSPHATASE; CHLORPYRIFOS; FEMALE; GENOTYPE; HUMANS; LIVER; MALE; METABOLIC DETOXICATION, DRUG; MIDDLE AGED; ORGANOPHOSPHORUS COMPOUNDS; PARAOXON;

EID: 33846451402     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.013193     Document Type: Article

References (34)

1. Adkins S, Gan KN, Mody M, and La Du BN (1993) Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191 for the respective A or B isozymes. Am J Hum Genet 52:598-608.
2. Aviram M, Dornfeld L, Rosenblat M, Volkova N, Kaplan M, Coleman R, Hayek T, Presser D, and Fuhrman B (2000) Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr 71:1062-1076.
3. Blatter Garin MC, James RW, Dussoix P, Blanche H, Passa P, Froguel P, and Ruiz J (1997) Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. J Clin Investig 99:62-66.
4. Blin N and Stafford DN (1976) A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res 3:2303.
5. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, and Furlong CE (2001) Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 68:1428-1436.
6. Chambers JE and Carr RL (1993) Inhibition patterns of brain acetylcholinesterase and hepatic and plasma aliesterases following exposures to three phosphorothionate insecticides and their oxons in rats. Fundam Appl Toxicol 21:111-119.
7. Chambers JE, Ma T, Boone JS, and Chambers HW (1994) Role of detoxication pathways in acute toxicity levels of phosphorothioate insecticides in the rat. Life Sci 54:1357-1364.
8. Cherry N, Mackness M, Durrington P, Povey A, Dippnall M, Smith T, and Mackness B (2002) Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip. Lancet 359:763-764.
9. Daly AK, Steen VM, Fairbrother KS, and Idle JR (1996) CYP2D6 multi-allelism. Methods Enzymol 272:199-210.
10. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, and Furlong CE (1996) The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nature (Lond) Genet 14:334-336.
11. Eckerson HW, Wyte CM, and La Du BN (1983) The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 35:1126-1138.
12. Furlong CE, Costa LG, Hassett C, Richter RJ, , , , , , , et al. (1993) Human and rabbit paraoxonases: purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification. Chem Biol Interact 87:35-48.
13. Gallo MA and Lawryk NJ (1991) Organophosphorus pesticides, in Handbook of Pesticide Toxicology (Hayes WJ and Laws ER eds), vol 2, pp 917-1123, Academic Press, San Diego.
14. Hernandez AF, Mackness B, Rodrigo L, Lopez O, Pla A, Gil F, , , , , et al. (2003) Paraoxonase activity and genetic polymorphisms in greenhouse workers with long-term pesticide exposure. Hum Exp Toxicol 22:565-574.
15. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, and Furlong CE (1993) The molecular basis of the human serum paraoxonase activity polymorphism. Nature (Lond) Genet 3:73-76.
16. Jarvik GP, Tsai NT, McKinstry LA, Wani R, Brophy VH, Richter RJ, , , , and (2002) Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol 22:1329-1333.
17. Karanth S, Olivier K, Liu J, and Pope C (2001) In vivo interaction between chlorpyrifos and parathion in adult rats: sequence of administration can markedly influence toxic outcome. Tox Appl Pharmacol 177:247-255.
18. Lee BW, London L, Paulauskis J, Myers J, and Christiani DC (2003) Association between human paraoxonase gene polymorphisms and chronic symptoms in pesticide-exposed workers. J Occup Environ Med 45:118-122.
19. Leviev I and James RW (2000) Promoter polymorphisms of human paraoxonase (PON1) gene and serum paraoxonase activities and concentrations. Arterioscl Thomb Vasc Biol 20:516-521.
20. Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A, Lusis AJ, and Furlong CE (2000) Catalytic efficiency determines the in vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 10:767-779.
21. Mackness B, Durrington P, Povey A, Thomson S, Dippnall M, Mackness M, Smith T, and Cherry N (2003) Paraoxonase and susceptibility to organophosphorus poisoning in farmers dipping sheep. Pharmacogenetics 13:81-88.
22. Mutch E, Blain PG, and Williams FM (1992) Interindividual variations in enzymes controlling organophosphate toxicity in man. Hum Exp Toxicol 11:109-116.
23. Mutch E, Blain PG, and Williams FM (1999) The role of metabolism in determining susceptibility to parathion toxicity in man. Toxicol Lett 107:177-187.
24. Mutch E, Daly AK, Leathart JBS, Blain PG, and Williams FM (2003) Do multiple cytochrome P450 isoforms contribute to parathion metabolism in man? Arch Toxicol 77:313-320.
25. Mutch E and Williams FM (2006) Diazinon, chlorpyrifos and parathion are metabolised by multiple cytochromes P450 in human liver. Toxicology 224:22-32.
26. O'Leary KA, Edwards RJ, Town MM, and Boobis AR (2005) Genetic and other sources of variation in the activity of serum paraoxonase/diazoxonase in humans: consequences for risk from exposure to diazinon. Pharmacogenet Genomics 15:51-60.
27. Senti M, Tomas M, Anglada R, Elosua R, Marrugat J, Covas MI, and Fito M (2003) Interrelationship of smoking, paraoxonase activity and leisure time physical activity: a population-based study. Eur J Int Med 14:178-184.
28. Shapiro SS and Wilk MB (1965) An analysis of variance for normality (complete samples). Biometrika 52:591-612.
29. Smith PK, Krohn RI, and Hermanson GT (1985) Measurement of protein using bicinchonic acid. Anal Biochem 150:76-85.
30. Sultatos LG and Minor LD (1986) Factors affecting the biotransformation of the pesticide parathion by the isolated perfused mouse liver. Drug Metab Dispos 14:214-220.
31. Sultatos LG, Shao M, and Murphy SD (1984) The role of hepatic bio-transformation in mediating the acute toxicity of the phosphorothionate insecticide chlorpyrifos. Toxicol Appl Pharmacol 73:60-68.
32. Tang J and Chambers JE (1999) Detoxication of paraoxon by rat liver homogenate and serum carboxylesterases and A-esterases. J Biochem Mol Tox 13:261-268.
33. Timchalk C, Kousba A, and Poet TS (2002) Monte Carlo analysis of the human chlorpyrifos-oxonase (PON1) polymorphism using a physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model. Toxicol Lett 135:51-59.
34. Yuknavage KL, Fenske RA, Kalman DA, Keifer MC, and Furlong CE (1997) Simulated dermal contamination with capillary samples and field cholinesterase monitoring. J Toxicol Environ Health 51:35-55.